Slide 1: Cryoport, Inc. Third Quarter Earnings Call
Cryoport, Inc. Calendar Year 2017 Third Quarter Earnings Call NASDAQ: CYRX 1
Slide 2: Safe Harbor – Forward Looking Statements
Safe Harbor – Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans
Slide 3: Cryoport has Undergone Material, Positive Changes Since Q1, 2017
Cryoport has Undergone Material, Positive Changes Since Q1, 2017 $12.00 Pre-Q1 2017 capital raise (March 28, 2017) As of October 31, 2017 2 approved CAR-T therapies with another BLA $10.00 0 approved CAR-T therapies filed earlier this week $8.00 2 commercial CAR-T agreements with the leading 0 comme
Slide 4: Clinical Trials Drive Revenue Growth
Clinical Trials Drive Revenue Growth FDAApprovals: - Novartis (KymriahTM) - Kite Pharma (YescartaTM) 195 172 20 17 82 93 82 73 Potential Annual Revenue per Trial ($15-75K) ($75-150K) ($200K-1M) ($ ($2M-20M) NASDAQ: CYRX 4
Slide 5: Supporting the Commercialization of Novartis' Kymriah
Cryoport is Supporting the Commercialization of Kymriah, Novartis’ First-to-Market CAR-T Cell Therapy Cryoport is the exclusive cold-chain solutions provider for Kymriah – 3 year agreement with renewal rights Novartis received first ever FDA approval for a CAR-T cell therapy, Kymriah™ (CTL019), for
Slide 6: Chosen to Support the Launch of Kite/Gilead's Yescarta
Cryoport has been Chosen to Support the Launch of Kite/Gilead’s CAR-T, Yescarta, which was Approved in October Cryoport will be the cold-chain solutions provider for axi-cel throughout the product’s life cycle For the past three decades, Kite has been at the forefront of cancer immunotherapy and a l
Slide 7: Primary Target Market: Regenerative Therapy
Primary Target Market: Regenerative Therapy Inflection point: Commercialization Ph. I: 307 has begun in 2017 934 (192 in 2015) Ph. II: 548 Novartis’ CAR-T drug, Kymriah, approved in August and Gilead/Kite therapy, Yescarta, approved in October Clinical trials underway At least 2-4 additional BLAs fo
Slide 8: C3 Shipper for Clients Requiring Reliable 2-8°C Logistics Solutions
C3 Shipper for Clients Requiring Reliable 2-8°C Logistics TM Solutions The introduction of C3 TM means that Cryoport can support the entire logistics continuum for regenerative medicine clinical and commercial programs The C3 Solution seamlessly integrates Cryoport’s TM expertise in packaging, infor
Slide 9: Client Base of Leading Companies
Client Base of Leading Companies Biopharma Reproductive Medicine Animal Health NASDAQ: CYRX 9
Slide 10: No Other Player with Comprehensive Logistics Solutions for Regenerative Therapy
No Other Player – with Comprehensive Logistics Solutions for the Regenerative Therapy Market Primary focus is on the large and rapidly growing Offers a comprehensive suite of solutions not Regenerative Therapy market available from any competitor Global regenerative therapy market expected to grow t
Slide 11: Cryoport is at an Important Inflection Point
Cryoport is at an Important Inflection Point Cryoport holds commercial support agreements with the two currently most important players (Novartis and Gilead/Kite Pharma) in the expanding CAR-T space Commercial agreements represent large sources of future revenue - considerably beyond what is achieve
Slide 12: Cryoport has a Scalable Business Model
Cryoport has a Scalable Business Model Continuing double-digit growth in all markets fueled by biopharma - increased 75.6% from 2016 to 2017 for the 9-month period ended September 30th Net revenue for the 9-month period vs. prior years ($mm) Gross margin % for the 9-month period vs. prioryears 50.0%
Slide 13: Revenue Trends
Revenue Trends All biopharma growth to-date has been generated without commercial assets Q3-2017 over Q3-2016 growth: +65% +12% +33% NASDAQ: CYRX 13
Slide 14: Financial Summary
Financial Summary 5-year net revenue CAGR of ~75% Statements of Operations Data (in thousands) 2012 2013 2014 2015 2016 '12 - '16 CAGR 9mos-2016 9mos-2017 YoY growth % Net Revenues $863 $2,194 $3,572 $5,525 $7,679 72.7% $5,450 $8,632 58.4% Biopharma 704 1,105 1,736 3,364 5,302 65.7% 3,756 6,597 75.6
Slide 15: Key Highlights
Key Highlights Nine month revenue growth of 58% year over year Impressive Supporting Novartis’ commercial launch of Kymriah revenue growth driven Novartis recently filed a BLA for second indication of Kymriah by robust Supporting Kite’s commercial launch of Yestcarta pipeline Biopharma revenue up 76
Slide 16: Thank you!
Science. Logistics. Certainty. Thank you! NASDAQ: CYRX 16